Myology research highlights
RSS feedGenetic and clinical databases to study the natural history of dystrophinopathies
In this publication, the authors studied the natural history of dystrophinopathies and the genotype-phenotype correlations made possible by the development of the clinical part of the French DMD database. The collection of 70,000 clinical data for 600 patients with an average longitudinal follow-up of 12years enabled clarification of the natural history of Duchenne and Becker … [Read more]
The Rag2-Il2rb-Dmd-mouse: an advanced model to evaluate transplantation strategies for muscular dystrophies
The development of innovative therapeutic strategies for muscular dystrophies, particularly cell-based approaches, is still a developing field. Although positive results have been obtained in animal models, they have rarely been confirmed in patients and resulted in very limited clinical improvements, suggesting some specificity in humans. These findings emphasized the need for an appropriate animal model … [Read more]
Adult centronuclear myopathies: A hospital-based study
Centronuclear myopathies (CNM) are rare inherited disorders characterized by nuclei placed in rows in the central part of the muscle fibres. Three CNM-causing genes have been identified, with MTM1 mutations provoking X-linked myotubular myopathy, DNM2 mutations provoking autosomal dominant (AD) CNM, and BIN1 mutations provoking autosomal recessive (AR) CNM. In this retrospective monocentric study, the … [Read more]
Long-term benefit of AAV-mediated miRNA therapy in dystrophic mice with chronic dilated cardiomyopathy
Dilated cardiomyopathy (DCM) is a leading cause of chronic morbidity and mortality in muscular dystrophy (MD) patients. Current pharmacological treatments are not yet able to counteract chronic myocardial wastage, thus novel therapies are being intensely explored. MicroRNAs have been implicated as fine regulators of cardiomyopathic progression. Previously, miR-669a downregulation has been linked to the severe … [Read more]
Monitoring disease progression in LGMD2I
Outcome measures for clinical trials in neuromuscular diseases are typically based on physical assessments, which are dependent on patient effort, combine the effort of different muscle groups, and may not be sensitive to progression over short trial periods in slow-progressing diseases. In this study, the authors hypothesised that quantitative fat imaging by MRI (Dixon technique) … [Read more]
Advances in Charcot-Marie-Tooth diseases
Charcot-Marie-Tooth (CMT) disease is the most common inherited neuromuscular disorder, with a fairly homogeneous clinical phenotype (progressive distal muscle weakness and atrophy, foot deformities, distal sensory loss, and depressed tendon reflexes). With more than 40 genes implicated, an update of the present and rather confusing classification of CMT is needed. Over the last few years, … [Read more]
A defect in the expression of ZNF37A is associated with impaired myogenesis DM1
Myotonic dystrophy type 1 (DM1) is an RNA-mediated disorder caused by a non-coding CTG repeat expansion that, in particular, provokes functional alteration of CUG-binding proteins. As a consequence, several genes with misregulated alternative splicing have been linked to clinical symptoms. In search for additional molecular mechanisms that would trigger functional defects in DM1, the authors … [Read more]
Description of a new gene that causes congenital myopathy
Congenital myopathies are heterogeneous inherited diseases of muscle characterized by a range of distinctive histologic abnormalities. Herein, the authors have studied a consanguineous family with congenital myopathy. Genome-wide linkage analysis and whole-exome sequencing identified a homozygous nonsense mutation in 3-hydroxyacyl-CoA dehydratase 1 (HACD1) in affected individuals. The mutation results in non-sense mediated decay of the … [Read more]
Eteplirsen for the treatment of DMD
In prior open-label studies, eteplirsen, a phosphorodiamidate morpholino oligomer (PMO), enabled dystrophin production in Duchenne muscular dystrophy (DMD) with genetic mutations amenable to skipping exon 51. The present study used a double-blind placebo-controlled protocol to test eteplirsen’s ability to induce dystrophin production and improve distance walked on the 6-minute walk test (6MWT). DMD boys aged … [Read more]
Development of a scale to assess upper limb function in DMD
An international Clinical Outcomes Group consisting of clinicians, scientists, patient advocacy groups, and industries identified a need for a scale to measure motor performance of the upper limb. This study reports the steps leading to the development of the Performance of the Upper Limb (PUL), a tool specifically designed for assessing upper limb function in … [Read more]